The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...
DexCom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, is ushering in the next era of transformative, ...
Supermodel Bambi Northwood-Blyth wears a Dexcom glucose monitor. So does your next-door neighbor with type 2 diabetes and ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System ...
Dexcom (NSDQ:DXCM) today announced the beginning of new CEO Jake Leach's tenure, starting with his presence at CES 2026.
Tandem Diabetes Care, Inc. TNDM announced that the in-warranty users of the t:slim X2 insulin pump in Canada can now access full compatibility with both Dexcom’s DXCM G7 and G6 Continuous Glucose ...
Dexcom is working closely with its insulin pump partners to ensure that Dexcom G7 15 Day will be compatible with automated insulin delivery systems upon launch. Dexcom G7 15 Day is expected to launch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback